Arrowhead Pharmaceuticals vs BridgeBio Pharma
ARWR and BBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and BBIO compare
BridgeBio Pharma is the larger company, worth 1.7 times as much as Arrowhead Pharmaceuticals ($14.7B against $8.5B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 16.8% for Arrowhead Pharmaceuticals).
Arrowhead Pharmaceuticals scores higher on the StockData Score (5 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | BBIO |
|---|---|---|
| Size and price | ||
| Market cap | $8.5B | $14.7B |
| Share price | $59.90 | $74.95 |
| Change, 1 year | 48.7% | 12.5% |
| Change, 5 years | −25.8% | 40.3% |
| Beta (5Y) | 1.73 | 1.13 |
| Employees | 711 | 834 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.6× (better) | 15.5× |
| P/B | 18.2× | – |
| FCF yield | −0.89% (better) | −2.5% |
| Fair value | $32.22 | – |
| Margin of safety | −85.9% | – |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 167% (better) |
| Revenue growth, 5Y average | 56.6% | 127% (better) |
| Profitability | ||
| Gross margin | – | 94.3% |
| Operating margin | −33.8% (better) | −38.5% |
| Net margin | −47.8% | – |
| FCF margin | −11.2% (better) | −39.1% |
| Return on equity | −64.8% | – |
| Financial health | ||
| Interest coverage | −2.4× (better) | −7.1× |
| Current ratio | 5.90 (better) | 2.09 |
| Altman Z-score | 2.56 (better) | 0.06 |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Buyback yield | – | 1.7% |
| Shareholder yield | 0.00% | 1.7% (better) |
| Ownership | ||
| Held by institutions | 84.6% | 99.1% |
| Held by insiders | 4.0% | 35.5% |
| Insider net buying, 12 months | −$37.3M (better) | −$105M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.9% | 15.6% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.